Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT03421431
Registration number
NCT03421431
Ethics application status
Date submitted
29/01/2018
Date registered
5/02/2018
Date last updated
16/09/2021
Titles & IDs
Public title
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis
Query!
Scientific title
A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
Query!
Secondary ID [1]
0
0
EDP 305-101
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Non-Alcoholic Steatohepatitis
0
0
Query!
Condition category
Condition code
Oral and Gastrointestinal
0
0
0
0
Query!
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Query!
Metabolic and Endocrine
0
0
0
0
Query!
Metabolic disorders
Query!
Diet and Nutrition
0
0
0
0
Query!
Obesity
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - EDP-305 Dose 1
Treatment: Drugs - EDP-305 Dose 2
Treatment: Drugs - Placebo
Experimental: EDP-305 Dose 1 - Subjects will take 2 tablets once a day orally for 12 weeks
Experimental: EDP-305 Dose 2 - Subjects will take 2 tablets once a day orally for 12 weeks
Placebo Comparator: Placebo - Subjects will take 2 tablets once a day orally for 12 weeks
Treatment: Drugs: EDP-305 Dose 1
Two tablets daily for 12 weeks
Treatment: Drugs: EDP-305 Dose 2
Two tablets daily for 12 weeks
Treatment: Drugs: Placebo
Two tablets daily for 12 weeks
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Mean Change From Baseline (Average) in Alanine Aminotransferase (ALT) at Week 12
Query!
Assessment method [1]
0
0
Blood samples were collected at specific timepoints for the laboratory evaluation to assess the ALT level. Baseline refers to the average of the screening and the Day 1 values; if either the screening or Day 1 values were missing, the non-missing value was used. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
Query!
Timepoint [1]
0
0
Baseline and Week 12
Query!
Secondary outcome [1]
0
0
Mean Change From Baseline in Percentage of Fat in the Liver as Assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF) at Week 12
Query!
Assessment method [1]
0
0
The liver fat percentage was assessed by MRI-PDFF, which is an established method that enables the quantification of fat content in the liver; the value of liver fat is expressed in percentage and ranges from 0 to 100% with higher values representing higher liver fat level. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
Query!
Timepoint [1]
0
0
Baseline and Week 12
Query!
Secondary outcome [2]
0
0
Mean Change From Baseline in Aspartate Aminotransferase to Platelet Ratio Index (APRI) at Week 12
Query!
Assessment method [2]
0
0
Blood samples were collected at specific timepoints for the laboratory evaluation to assess the aspartate aminotransferase (AST) level and platelet count. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. The APRI score (AST to platelet ratio index) is an index comprised of biochemical values and is used to determine the degree of hepatic fibrosis. APRI is calculated from the level of AST measured in a blood test (international units per liter [IU/L]) and platelet count (10^9/L) according to the following formula:
APRI = ([AST value in IU/L / upper limit of the normal range of AST] / [platelet count in 10^9/L]) × 100.
In general, APRI scores range from 0 to >2.0, where scores <0.5 indicate no significant fibrosis, scores >1.5 indicate significant fibrosis, and scores >2.0 have been shown to be best correlated with the presence of cirrhosis. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
Query!
Timepoint [2]
0
0
Baseline and Week 12
Query!
Secondary outcome [3]
0
0
Mean Change From Baseline in Triglycerides (TG) at Week 12
Query!
Assessment method [3]
0
0
Blood samples were collected at specific timepoints for the laboratory evaluation to assess the TG level. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
Query!
Timepoint [3]
0
0
Baseline and Week 12
Query!
Secondary outcome [4]
0
0
Mean Change From Baseline in Total Cholesterol at Week 12
Query!
Assessment method [4]
0
0
Blood samples were collected at specific timepoints for the laboratory evaluation to assess the total cholesterol level. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
Query!
Timepoint [4]
0
0
Baseline and Week 12
Query!
Secondary outcome [5]
0
0
Mean Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at Week 12
Query!
Assessment method [5]
0
0
Blood samples were collected at specific timepoints for the laboratory evaluation to assess the HDL-C level. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
Query!
Timepoint [5]
0
0
Baseline and Week 12
Query!
Secondary outcome [6]
0
0
Mean Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12
Query!
Assessment method [6]
0
0
Blood samples were collected at specific timepoints for the laboratory evaluation to assess the LDL-C level. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
Query!
Timepoint [6]
0
0
Baseline and Week 12
Query!
Secondary outcome [7]
0
0
Mean Change From Baseline in Adiponectin at Week 12
Query!
Assessment method [7]
0
0
Blood samples were collected at specific timepoints for the laboratory evaluation to assess the adiponectin level. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
Query!
Timepoint [7]
0
0
Baseline and Week 12
Query!
Secondary outcome [8]
0
0
Mean Change From Baseline in Apolipoproteins A1 (ApoA-1) at Week 12
Query!
Assessment method [8]
0
0
Blood samples were collected at specific timepoints for the laboratory evaluation to assess the ApoA-1 level. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
Query!
Timepoint [8]
0
0
Baseline and Week 12
Query!
Secondary outcome [9]
0
0
Mean Change From Baseline in Apolipoproteins B (ApoB) at Week 12
Query!
Assessment method [9]
0
0
Blood samples were collected at specific timepoints for the laboratory evaluation to assess the ApoB level. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
Query!
Timepoint [9]
0
0
Baseline and Week 12
Query!
Secondary outcome [10]
0
0
Mean Change From Baseline in Apolipoproteins C3 (ApoC3) at Week 12
Query!
Assessment method [10]
0
0
Blood samples were collected at specific timepoints for the laboratory evaluation to assess the ApoC3 level. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
Query!
Timepoint [10]
0
0
Baseline and Week 12
Query!
Secondary outcome [11]
0
0
Mean Change From Baseline in Fasting Blood Glucose at Week 12
Query!
Assessment method [11]
0
0
Blood samples were collected at specific timepoints for the laboratory evaluation to assess the fasting glucose level. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
Query!
Timepoint [11]
0
0
Baseline and Week 12
Query!
Secondary outcome [12]
0
0
Mean Change From Baseline in Fasting Insulin at Week 12
Query!
Assessment method [12]
0
0
Blood samples were collected at specific timepoints for the laboratory evaluation to assess the fasting insulin (in micro International units per milliliter [µIU/mL]). Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
Query!
Timepoint [12]
0
0
Baseline and Week 12
Query!
Secondary outcome [13]
0
0
Mean Change From Baseline in Homeostasis Model Assessment (HOMA) Index for Nondiabetic Participants at Week 12
Query!
Assessment method [13]
0
0
Blood samples were collected at specific timepoints for the laboratory evaluation; from the results of fasting glucose and insulin, an insulin resistance (IR) was estimated for the nondiabetic participants using the HOMA-IR computer algorithm. A higher HOMA-IR indicates a higher degree of insulin resistance. Participants who were not considered as having type 2 diabetes mellitus (T2DM) were identified as nondiabetic. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
Query!
Timepoint [13]
0
0
Baseline and Week 12
Query!
Secondary outcome [14]
0
0
Mean Change From Baseline in HOMA Index for Diabetic Participants at Week 12
Query!
Assessment method [14]
0
0
Blood samples were collected at specific timepoints for the laboratory evaluation; from the results of fasting glucose and insulin, an insulin resistance (IR) was estimated for the nondiabetic participants using the HOMA-IR computer algorithm. A higher HOMA-IR indicates a higher degree of insulin resistance. Participants who were considered as having T2DM were identified as diabetic. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
Query!
Timepoint [14]
0
0
Baseline and Week 12
Query!
Secondary outcome [15]
0
0
Mean Change From Baseline in Glycated Hemoglobin (HbA1c) in Participants With T2DM at Week 12
Query!
Assessment method [15]
0
0
Blood samples were collected at specific timepoints for the laboratory evaluation to assess the HbA1c. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
Query!
Timepoint [15]
0
0
Baseline and Week 12
Query!
Secondary outcome [16]
0
0
Maximum Plasma Concentration (Cmax) of EDP-305 on Day 1 and Week 12
Query!
Assessment method [16]
0
0
The Cmax is the maximum observed plasma concentration, which was measured for EDP-305 on Day 1 and Week 12 for the samples collected according to the intensive sampling scheme for the participants in the Pharmacokinetic (PK) Population.
Query!
Timepoint [16]
0
0
Predose and 2, 6, and 8 hours postdose on Day 1 and on Day 84 (Week 12)
Query!
Secondary outcome [17]
0
0
Time to Reach Maximum Plasma Concentration (Tmax) of EDP-305 on Day 1 and at Week 12
Query!
Assessment method [17]
0
0
The Tmax was measured for EDP-305 on Day 1 and at Week 12 for the samples collected according to the intensive sampling scheme for the participants in the PK Population.
Query!
Timepoint [17]
0
0
Predose and 2, 6, and 8 hours postdose on Day 1 and on Day 84 (Week 12)
Query!
Secondary outcome [18]
0
0
Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero to the Time of the Last Quantifiable Concentration (AUC[Last]) of EDP-305 on Day 1 and at Week 12
Query!
Assessment method [18]
0
0
AUC(last) is defined as the area under the plasma concentration-time curve from time zero to time the last quantifiable concentration, computed using the linear up/log down trapezoidal rule. AUC(last) was computed for EDP-305 on Day 1 and Week 12 for the samples collected according to the intensive sampling scheme for the participants in the PK Population.
Query!
Timepoint [18]
0
0
Predose and 2, 6, and 8 hours postdose on Day 1 and on Day 84 (Week 12)
Query!
Secondary outcome [19]
0
0
Cmax of EP-022571 on Day 1 and at Week 12
Query!
Assessment method [19]
0
0
The Cmax is the maximum observed plasma concentration, which was measured for EP-022571 (a metabolite of EDP-305) on Day 1 and Week 12 for the samples collected according to the intensive sampling scheme for the participants in the PK Population.
Query!
Timepoint [19]
0
0
Predose and 2, 6, and 8 hours postdose on Day 1 and on Day 84 (Week 12)
Query!
Secondary outcome [20]
0
0
Tmax of EP-022571 on Day 1 and at Week 12
Query!
Assessment method [20]
0
0
The Tmax was measured for EP-022571 (a metabolite of EDP-305) on Day 1 and at Week 12 for the samples collected according to the intensive sampling scheme for the participants in the PK Population.
Query!
Timepoint [20]
0
0
Predose and 2, 6, and 8 hours postdose on Day 1 and on Day 84 (Week 12)
Query!
Secondary outcome [21]
0
0
AUC(Last) of EP-022571 on Day 1 and at Week 12
Query!
Assessment method [21]
0
0
AUC(last) is defined as the area under the plasma concentration-time curve from time zero to time the last quantifiable concentration, computed using the linear up/log down trapezoidal rule. AUC(last) was computed for EP-022571 (a metabolite of EDP-305) on Day 1 and Week 12 for the samples collected according to the intensive sampling scheme for the participants in the PK Population.
Query!
Timepoint [21]
0
0
Predose and 2, 6, and 8 hours postdose on Day 1 and on Day 84 (Week 12)
Query!
Secondary outcome [22]
0
0
Cmax of EP-022572 on Day 1 and at Week 12
Query!
Assessment method [22]
0
0
The Cmax is the maximum observed plasma concentration, which was measured for EP-022572 (a metabolite of EDP-305) on Day 1 and Week 12 for the samples collected according to the intensive sampling scheme for the participants in the PK Population.
Query!
Timepoint [22]
0
0
Predose and 2, 6, and 8 hours postdose on Day 1 and on Day 84 (Week 12)
Query!
Secondary outcome [23]
0
0
Tmax of EP-022572 on Day 1 and at Week 12
Query!
Assessment method [23]
0
0
The Tmax was measured for EP-022572 (a metabolite of EDP-305) on Day 1 and at Week 12 for the samples collected according to the intensive sampling scheme for the participants in the PK Population.
Query!
Timepoint [23]
0
0
Predose and 2, 6, and 8 hours postdose on Day 1 and on Day 84 (Week 12)
Query!
Secondary outcome [24]
0
0
AUC(Last) of EP-022572 on Day 1 and at Week 12
Query!
Assessment method [24]
0
0
AUC(last) is defined as the area under the plasma concentration-time curve from time zero to time the last quantifiable concentration, computed using the linear up/log down trapezoidal rule. AUC(last) was computed for EP-022572 (a metabolite of EDP-305) on Day 1 and Week 12 for the samples collected according to the intensive sampling scheme for the participants in the PK Population.
Query!
Timepoint [24]
0
0
Predose and 2, 6, and 8 hours postdose on Day 1 and on Day 84 (Week 12)
Query!
Secondary outcome [25]
0
0
Cmax of EP-022679 on Day 1 and at Week 12
Query!
Assessment method [25]
0
0
The Cmax is the maximum observed plasma concentration, which was measured for EP-022679 (a metabolite of EDP-305) on Day 1 and Week 12 for the samples collected according to the intensive sampling scheme for the participants in the PK Population.
Query!
Timepoint [25]
0
0
Predose and 2, 6, and 8 hours postdose on Day 1 and on Day 84 (Week 12)
Query!
Secondary outcome [26]
0
0
Tmax of EP-022679 on Day 1 and at Week 12
Query!
Assessment method [26]
0
0
The Tmax was measured for EP-022679 (a metabolite of EDP-305) on Day 1 and at Week 12 for the samples collected according to the intensive sampling scheme for the participants in the PK Population.
Query!
Timepoint [26]
0
0
Predose and 2, 6, and 8 hours postdose on Day 1 and on Day 84 (Week 12)
Query!
Secondary outcome [27]
0
0
AUC(Last) of EP-022679 on Day 1 and at Week 12
Query!
Assessment method [27]
0
0
AUC(last) is defined as the area under the plasma concentration-time curve from time zero to time the last quantifiable concentration, computed using the linear up/log down trapezoidal rule. AUC(last) was computed for EP-022679 (a metabolite of EDP-305) on Day 1 and Week 12 for the samples collected according to the intensive sampling scheme for the participants in the PK Population.
Query!
Timepoint [27]
0
0
Predose and 2, 6, and 8 hours postdose on Day 1 and on Day 84 (Week 12)
Query!
Secondary outcome [28]
0
0
Mean Change From Baseline in Body Weight at Week 12
Query!
Assessment method [28]
0
0
Body weight was measured at specific timepoints for the participants. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
Query!
Timepoint [28]
0
0
Baseline and Week 12
Query!
Secondary outcome [29]
0
0
Mean Change From Baseline in Waist to Hip (WTH) Ratio at Week 12
Query!
Assessment method [29]
0
0
The WTH ratio is calculated as the ratio of waist to hip circumference, which was measured at specific timepoints. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
Query!
Timepoint [29]
0
0
Baseline and Week 12
Query!
Secondary outcome [30]
0
0
Mean Change From Baseline in Fibroblast Growth Factor 19 (FGF19) by Nominal Timepoint (Intensive Pharmacodynamic [PD] Samples) at Week 12
Query!
Assessment method [30]
0
0
Blood samples were collected according to the intensive sampling scheme at specific timepoints to assess the PD marker: FGF19. Baseline refers to the last non-missing predose value collected prior to the most recent dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
Query!
Timepoint [30]
0
0
Predose and 2, 6, and 8 hours postdose on Day 1 and Day 84 (Week 12)
Query!
Secondary outcome [31]
0
0
Mean Change From Baseline in FGF19 by Bin Timepoint (Sparse PD Samples) at Week 12
Query!
Assessment method [31]
0
0
Blood samples were collected according to the sparse sampling scheme at specific timepoints to assess the PD marker: FGF19. Baseline refers to the last non-missing predose value collected prior to the most recent dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
Query!
Timepoint [31]
0
0
Predose and two samples postdose (first sample between 1 to 3 hours postdose and second sample 1 hour later than fist sample) on Day 1 and Day 84 (Week 12)
Query!
Secondary outcome [32]
0
0
Mean Change From Baseline in 7a-Hydroxy-4-Cholestene-3-One (C4) by Nominal Timepoint (Intensive PD Samples) at Week 12
Query!
Assessment method [32]
0
0
Blood samples were collected according to the intensive sampling scheme at specific timepoints to assess the PD marker: C4. Baseline refers to the last non-missing predose value collected prior to the most recent dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
Query!
Timepoint [32]
0
0
Predose and 2, 6, and 8 hours postdose on Day 1 and Day 84 (Week 12)
Query!
Secondary outcome [33]
0
0
Mean Change From Baseline in C4 by Bin Timepoint (Sparse PD Samples) at Week 12
Query!
Assessment method [33]
0
0
Blood samples were collected according to the sparse sampling scheme at specific timepoints to assess the PD marker: C4. Baseline refers to the last non-missing predose value collected prior to the most recent dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
Query!
Timepoint [33]
0
0
Predose and two samples postdose (first sample between 1 to 3 hours postdose and second sample 1 hour later than fist sample) on Day 1 and Day 84 (Week 12)
Query!
Secondary outcome [34]
0
0
Mean Change From Baseline in Bile Acid (BA) by Nominal Timepoint (Intensive PD Samples) at Week 12
Query!
Assessment method [34]
0
0
Blood samples were collected according to the intensive sampling scheme at specific timepoints to assess the PD marker: BA. Baseline refers to the last non-missing predose value collected prior to the most recent dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
Query!
Timepoint [34]
0
0
Predose and 2, 6, and 8 hours postdose on Day 1 and Day 84 (Week 12)
Query!
Secondary outcome [35]
0
0
Mean Change From Baseline in BA by Bin Timepoint (Sparse PD Samples) at Week 12
Query!
Assessment method [35]
0
0
Blood samples were collected according to the sparse sampling scheme at specific timepoints to assess the PD marker: BA. Baseline refers to the last non-missing predose value collected prior to the most recent dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.
Query!
Timepoint [35]
0
0
Predose and two samples postdose (first sample between 1 to 3 hours postdose and second sample 1 hour later than fist sample) on Day 1 and Day 84 (Week 12)
Query!
Eligibility
Key inclusion criteria
- An informed consent document must be signed and dated by the subject
- Male and female subjects of any ethnic origin between the ages of 18 and 75 years,
inclusive
- Male or female with presence of NASH by:
- Histologic evidence on a historical liver biopsy within 24 months of Screening
consistent with NASH with fibrosis (no cirrhosis), and elevated ALT at Screening
AND Screening MRI PDFF with >8 % steatosis OR
- Phenotypic diagnosis of NASH based on elevated ALT and diagnosis of T2DM or
pre-diabetes AND Screening MRI PDFF with >8 % steatosis
- Body mass index (BMI) >25 kg/m2; for Asian-Americans, BMI >23 kg/m2
- Female subjects of childbearing potential must agree to use two effective methods of
contraception from the date of Screening until 90 days after the last dose of EDP-305.
- Subject must be willing and able to adhere to the assessments, visit schedules,
prohibitions and restrictions, as described in this protocol
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
75
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Laboratory Screening Results:
- Total bilirubin > ULN (normal range 0.2-1.2 mg/dL)
- Total white blood cells (WBC) <3,000 cells/mm3
- Absolute neutrophil count (ANC) <1,500 cells/mm3
- Platelet count <140,000/mm3
- Prothrombin time (international normalized ratio, INR) > 1.2
- Creatine kinase above the upper limit of normal (ULN) except when in relation
with intense exercise
- Serum creatinine >2 mg/dL or creatinine clearance <60 ml/min (based on Cockroft
Gault method)
- Known history of alpha-1-antitrypsin deficiency
- Use of an experimental treatment for NASH within the past 6 months
- Use of immunosuppressant (eg, corticosteroids) for more than 2 weeks in duration
within 1 year prior to Screening and during the course of the study
- Use of experimental or unapproved drugs within a year of Screening
- Any other condition(s) (including cardiovascular diseases) that would compromise the
safety of the subject or compromise the quality of the clinical study, as judged by
the Principal Investigator (PI)
- Pregnant or nursing females
- Recipients of liver or other organ transplantation or anticipated need for orthotropic
organ transplantation in one year as determined by a Model for End-Stage Liver Disease
(MELD) Score = 15
- Clinical suspicion of advanced liver disease or cirrhosis
- Coexisting liver or biliary diseases, such as primary sclerosing cholangitis (PSC),
choledocholithiasis, acute or chronic hepatitis, autoimmune hepatitis, alcoholic liver
disease, acute infection of bile duct system or gall bladder, history of
gastrointestinal bleeding (secondary to portal hypertension), cirrhosis
- Suspicion of cancer (eg, liver cancer) with the exception of basal cell carcinoma that
has been resected
- Cirrhosis with or without complications, including history or presence of: spontaneous
bacterial peritonitis, hepatocellular carcinoma, bilirubin > 2xULN
- Hepatorenal syndrome (type I or II) or Screening serum creatinine > 2 mg/dL (178
µmol/L)
- Prior variceal hemorrhage, uncontrolled encephalopathy, Child-Pugh Class A, B, and C,
esophageal varices, or refractory ascites within the previous 6 months of Screening
(defined as date informed consent signed)
- Any condition possibly affecting drug absorption (eg, gastrectomy <3 years prior to
Screening)
- Subject has received an investigational agent or vaccine within 30 days, or a
biological product within 3 months or 5 elimination half-lives (whichever is longer)
prior to the planned intake of study drug. NOTE: Flu vaccine will be allowed upon
Medical Monitor's approval
- Use of a new statin regimen from Screening and throughout study duration. NOTE:
Subjects on a stable dose of statins for at least three months prior to Screening are
allowed. No dose modification during the study will be allowed.
- Current use of fibrates. Note: Subjects who discontinued fibrates for at least 3
months before Screening can participate
- Clinically significant history of drug sensitivity or allergy, as determined by the PI
- Uncontrolled diabetes mellitus (ie, HbA1c =9% or higher) 60 days prior to Day 1
- Subjects with contraindications to MRI imaging, or not being able to have the MRI
performed
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
25/04/2018
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
10/07/2019
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
134
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Georgia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Illinois
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Indiana
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Kansas
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Louisiana
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Maryland
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Michigan
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Missouri
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
New Jersey
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
New York
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
North Carolina
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Ohio
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Pennsylvania
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Tennessee
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Texas
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Utah
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Virginia
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Washington
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Wisconsin
Query!
Country [24]
0
0
Canada
Query!
State/province [24]
0
0
Ontario
Query!
Country [25]
0
0
Canada
Query!
State/province [25]
0
0
Quebec
Query!
Country [26]
0
0
France
Query!
State/province [26]
0
0
Paris
Query!
Country [27]
0
0
France
Query!
State/province [27]
0
0
Pessac
Query!
Country [28]
0
0
France
Query!
State/province [28]
0
0
Strasbourg
Query!
Country [29]
0
0
New Zealand
Query!
State/province [29]
0
0
Auckland
Query!
Country [30]
0
0
Puerto Rico
Query!
State/province [30]
0
0
San Juan
Query!
Country [31]
0
0
United Kingdom
Query!
State/province [31]
0
0
Cambridgeshire
Query!
Country [32]
0
0
United Kingdom
Query!
State/province [32]
0
0
Greater London
Query!
Country [33]
0
0
United Kingdom
Query!
State/province [33]
0
0
Nottinghamshire
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Enanta Pharmaceuticals, Inc
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/Industry
Query!
Name [1]
0
0
ICON Clinical Research
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Other collaborator category [2]
0
0
Other
Query!
Name [2]
0
0
Triangle Biostatistics
Query!
Address [2]
0
0
Query!
Country [2]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
A randomized, double-blind study to assess the safety, tolerability, PK and efficacy of
EDP-305 in subjects with Non-Alcoholic Steatohepatitis
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT03421431
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Nathalie Adda, MD
Query!
Address
0
0
Enanta Pharmaceuticals, Inc
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT03421431
Download to PDF